Stock A207940 SAMSUNG BIOLOGICS CO.,LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Funds and ETFs Samsung Biologics Co.,Ltd.

Equities

A207940

KR7207940008

Pharmaceuticals

End-of-day quote Korea S.E.
Other stock markets
 23:00:00 25/04/2024 BST 		5-day change 1st Jan Change
770,000 KRW -1.28% Intraday chart for Samsung Biologics Co.,Ltd. -1.41% +1.32%
04-25 Samsung Bioepis Granted Approval to Market Autoimmune Treatment in Europe MT
04-25 Samsung Biologics Posts Higher Q1 Profit, Sales MT

ETFs positioned on Samsung Biologics Co.,Ltd.

Name Weight AuM 1st Jan change Investor Rating
KRANESHARES EMERGING MARKET HEALTHCARE INDEX ETF - DISTRIBUTING - USD ETF KraneShares Emerging Market Healthcare Index ETF - Distributing - USD
4.63% 2 M€ -14.14%
FIRST TRUST BICK INDEX ETF - USD ETF First Trust BICK Index ETF - USD
0.92% 11 M€ -.--% -
NOMURA NEXT FUNDS EMERGING MARKET EQUITY MSCI-EM (UNHEDGED) ETF - JPY ETF Nomura NEXT FUNDS Emerging Market Equity MSCI-EM (Unhedged) ETF - JPY
0.43% 15 M€ +11.24%
AMUNDI INDEX MSCI EMERGING MARKETS UCITS ETF DR (D) - EUR ETF AMUNDI INDEX MSCI EMERGING MARKETS UCITS ETF DR (D) - EUR
0.15% 441 M€ +4.60% -
AMUNDI INDEX MSCI EMERGING MARKETS UCITS ETF DR (C) - EUR ETF AMUNDI INDEX MSCI EMERGING MARKETS UCITS ETF DR (C) - EUR
0.15% 2,808 M€ +5.90% -
AMUNDI INDEX MSCI EMERGING MARKETS UCITS ETF - USD ETF AMUNDI INDEX MSCI EMERGING MARKETS UCITS ETF - USD
0.15% 149 M€ +2.17% -
SIMPLIFY EMERGING MARKETS PLUS DOWNSIDE CONVEXITY ETF - USD ETF Simplify Emerging Markets Plus Downside Convexity ETF - USD
0.13% 4 M€ -4.41% -
GOLDMAN SACHS ACTIVEBETA EMERGING MARKETS EQUITY UCITS ETF - ACC - USD ETF Goldman Sachs ActiveBeta Emerging Markets Equity UCITS ETF - Acc - USD
0.07% 11 M€ +1.79%
LEADERSHARES EQUITY SKEW ETF - USD ETF LeaderShares Equity Skew ETF - USD
0.05% 117 M€ +1.11% -
DEMOCRACY INTERNATIONAL FUND ETF - USD ETF Democracy International Fund ETF - USD
0.04% 7 M€ +1.95% -
VANGUARD LIFESTRATEGY 80% EQUITY UCITS ETF - DISTRIBUTING - EUR ETF Vanguard LifeStrategy 80% Equity UCITS ETF - Distributing - EUR
0.02% 34 M€ +6.71% -
VANGUARD LIFESTRATEGY 60% EQUITY UCITS ETF - ACC - EUR ETF Vanguard LifeStrategy 60% Equity UCITS ETF - Acc - EUR
0.01% 302 M€ +3.80% -
VANGUARD LIFESTRATEGY 60% EQUITY UCITS ETF - DISTRIBUTING - EUR ETF Vanguard LifeStrategy 60% Equity UCITS ETF - Distributing - EUR
0.01% 39 M€ +3.67% -
VANGUARD LIFESTRATEGY 80% EQUITY UCITS ETF ACC - EUR ETF Vanguard LifeStrategy 80% Equity UCITS ETF Acc - EUR
0.01% 389 M€ +6.83% -
VANGUARD LIFESTRATEGY 40% EQUITY UCITS ETF ACC - EUR ETF Vanguard LifeStrategy 40% Equity UCITS ETF Acc - EUR
0.01% 108 M€ +2.03% -
VANGUARD LIFESTRATEGY 40% EQUITY UCITS ETF - DISTRIBUTING - EUR ETF Vanguard LifeStrategy 40% Equity UCITS ETF - Distributing - EUR
0.01% 17 M€ +1.44% -
HORIZONS SEASONAL ROTATION ETF - CAD ETF Horizons Seasonal Rotation ETF - CAD
0.01% 147 M€ +4.88% -
VANGUARD LIFESTRATEGY 20% EQUITY UCITS ETF ACC - EUR ETF Vanguard LifeStrategy 20% Equity UCITS ETF Acc - EUR
0.01% 52 M€ -0.60% -
VANGUARD LIFESTRATEGY 20% EQUITY UCITS ETF - DISTRIBUTING - EUR ETF Vanguard LifeStrategy 20% Equity UCITS ETF - Distributing - EUR
0.01% 8 M€ -0.60% -
IMGP RBA RESPONSIBLE GLOBAL ALLOCATION ETF - USD ETF iMGP RBA Responsible Global Allocation ETF - USD
0.00% 7 M€ +0.11% -
UNLIMITED HFND MULTI-STRATEGY RETURN TRACKER ETF - USD ETF Unlimited HFND Multi-Strategy Return Tracker ETF - USD
0.00% 34 M€ +2.14% -
12

Company Profile

Samsung Biologics Co Ltd is a Korea-based company primarily engaged in development, manufacture and distribution of biological products. The Company, as a contract manufacturing organization (CMO), mainly develops and manufactures antibody drugs used for treatment of cancer, autoimmune disease, diabetes and chronic diseases. It also provides cell line development and process development services. The Company distributes its products in domestic and overseas markets.
Sector
Pharmaceuticals
Calendar
23/07/2024 - Q2 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Ratings for Samsung Biologics Co.,Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
770,000 KRW
Average target price
1,032,273 KRW
Spread / Average Target
+34.06%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

1st Jan change Capi.
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+1.32% 39.82B
CSL LIMITED Stock CSL Limited
-4.66% 86.13B
BIOGEN INC. Stock Biogen Inc.
-19.27% 30.42B
UCB Stock UCB
+57.86% 25.23B
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-16.09% 15.35B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-9.14% 11.95B
INCYTE CORPORATION Stock Incyte Corporation
-17.69% 11.6B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-43.00% 11.51B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+5.24% 8.71B
INNOVENT BIOLOGICS, INC. Stock Innovent Biologics, Inc.
-8.42% 8.12B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. A207940 Stock
  4. Funds and ETFs Samsung Biologics Co.,Ltd.